Table 5.
Summary of Death With Ofatumumab Therapy
| Death* | FA-ref (n = 59) |
BF-ref (n = 79) |
||
|---|---|---|---|---|
| No. of Patients | % | No. of Patients | % | |
| Total deaths | 6 | 10 | 5 | 6 |
| Cause of death | ||||
| Sepsis/septic shock | 3 | 5 | 1 | 1 |
| Pneumonia | 2 | 3 | 2 | 3 |
| CLL Richter's transformation | 1 | 2 | 0 | 0 |
| Myocardial infarction | 0 | 0 | 1 | 1 |
| Disease progression | 0 | 0 | 1 | 1 |
Abbreviations: FA-ref, fludarabine and alemtuzumab refractory; BF-ref, bulky fludarabine refractory; CLL, chronic lymphocytic leukemia.
*
Occurring within 30 days of the last ofatumumab infusion.